MNMD - long - multi catalyst play - risky before 03/07/2024
Mind Medicine Inc is a psychedelic medicine biotech company that discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The firm is having an approach towards developing the next generation of psychedelic inspired medicines and therapies.
This is not a financial advice!
4 upcoming catalysts 03/07/2024 , 03/31/2024, 06/30/2024 and 12/31/2024
2024-03-01 MNMD Reiterates Buy 75.00 Maintains HC Wainwright & Co.
Keep in mind the first catalyst is very close and we had already a nice run up. You can enter after the data release.
We need to stay in a bullish overal sentiment of the market. If we see a corretion, this play might doesn't work.
Keep an eye on 9, 11, 13, 16, 20, 24 levels, needs to get broken for a further upmove. You can take partial profits at these levels if u want to lock in gains.
SL under 4.5
TPs approx. 33 longterm
Most info on the chart.
Trade carefully!
This is not a financial advice!
4 upcoming catalysts 03/07/2024 , 03/31/2024, 06/30/2024 and 12/31/2024
2024-03-01 MNMD Reiterates Buy 75.00 Maintains HC Wainwright & Co.
Keep in mind the first catalyst is very close and we had already a nice run up. You can enter after the data release.
We need to stay in a bullish overal sentiment of the market. If we see a corretion, this play might doesn't work.
Keep an eye on 9, 11, 13, 16, 20, 24 levels, needs to get broken for a further upmove. You can take partial profits at these levels if u want to lock in gains.
SL under 4.5
TPs approx. 33 longterm
Most info on the chart.
Trade carefully!
تعليق:
03/27/2024
Mind Medicine (NASDAQ:MNMD) is Leading the Surge in Psychedelic Therapies
Mind Medicine (NASDAQ:MNMD) is Leading the Surge in Psychedelic Therapies
News from today:
MindMed shares are trading higher after the company received FDA Breakthrough Therapy Designation for its MM120 program in generalized anxiety disorder. The company also announced 12-week durability data from its Phase 2B study of MM120.